These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35166140)

  • 1. A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.
    Maples-Keller JL; Norrholm SD; Burton M; Reiff C; Coghlan C; Jovanovic T; Yasinski C; Jarboe K; Rakofsky J; Rauch S; Dunlop BW; Rothbaum BO
    J Psychopharmacol; 2022 Mar; 36(3):368-377. PubMed ID: 35166140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects.
    Vizeli P; Straumann I; Duthaler U; Varghese N; Eckert A; Paulus MP; Risbrough V; Liechti ME
    Front Pharmacol; 2022; 13():906639. PubMed ID: 35910354
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).
    Young MB; Norrholm SD; Khoury LM; Jovanovic T; Rauch SAM; Reiff CM; Dunlop BW; Rothbaum BO; Howell LL
    Psychopharmacology (Berl); 2017 Oct; 234(19):2883-2895. PubMed ID: 28741031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning.
    Young MB; Andero R; Ressler KJ; Howell LL
    Transl Psychiatry; 2015 Sep; 5(9):e634. PubMed ID: 26371762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats.
    Hake HS; Davis JKP; Wood RR; Tanner MK; Loetz EC; Sanchez A; Ostrovskyy M; Oleson EB; Grigsby J; Doblin R; Greenwood BN
    Physiol Behav; 2019 Feb; 199():343-350. PubMed ID: 30529341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
    Mithoefer MC; Wagner MT; Mithoefer AT; Jerome L; Doblin R
    J Psychopharmacol; 2011 Apr; 25(4):439-52. PubMed ID: 20643699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
    Mithoefer MC; Mithoefer AT; Feduccia AA; Jerome L; Wagner M; Wymer J; Holland J; Hamilton S; Yazar-Klosinski B; Emerson A; Doblin R
    Lancet Psychiatry; 2018 Jun; 5(6):486-497. PubMed ID: 29728331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexamethasone facilitates fear extinction and safety discrimination in PTSD: A placebo-controlled, double-blind study.
    Michopoulos V; Norrholm SD; Stevens JS; Glover EM; Rothbaum BO; Gillespie CF; Schwartz AC; Ressler KJ; Jovanovic T
    Psychoneuroendocrinology; 2017 Sep; 83():65-71. PubMed ID: 28595089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditioned fear and extinction learning performance and its association with psychiatric symptoms in active duty Marines.
    Acheson DT; Geyer MA; Baker DG; Nievergelt CM; Yurgil K; Risbrough VB;
    Psychoneuroendocrinology; 2015 Jan; 51():495-505. PubMed ID: 25444643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with a heat-killed preparation of Mycobacterium vaccae after fear conditioning enhances fear extinction in the fear-potentiated startle paradigm.
    Hassell JE; Fox JH; Arnold MR; Siebler PH; Lieb MW; Schmidt D; Spratt EJ; Smith TM; Nguyen KT; Gates CA; Holmes KS; Schnabel KS; Loupy KM; Erber M; Lowry CA
    Brain Behav Immun; 2019 Oct; 81():151-160. PubMed ID: 31175996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
    Mitchell JM; Bogenschutz M; Lilienstein A; Harrison C; Kleiman S; Parker-Guilbert K; Ot'alora G M; Garas W; Paleos C; Gorman I; Nicholas C; Mithoefer M; Carlin S; Poulter B; Mithoefer A; Quevedo S; Wells G; Klaire SS; van der Kolk B; Tzarfaty K; Amiaz R; Worthy R; Shannon S; Woolley JD; Marta C; Gelfand Y; Hapke E; Amar S; Wallach Y; Brown R; Hamilton S; Wang JB; Coker A; Matthews R; de Boer A; Yazar-Klosinski B; Emerson A; Doblin R
    Nat Med; 2021 Jun; 27(6):1025-1033. PubMed ID: 33972795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
    Mithoefer MC; Feduccia AA; Jerome L; Mithoefer A; Wagner M; Walsh Z; Hamilton S; Yazar-Klosinski B; Emerson A; Doblin R
    Psychopharmacology (Berl); 2019 Sep; 236(9):2735-2745. PubMed ID: 31065731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial.
    Ching TH; Williams MT; Wang JB; Jerome L; Yazar-Klosinski B; Emerson A; Doblin R
    J Psychopharmacol; 2022 Aug; 36(8):974-986. PubMed ID: 35727042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.
    Ot'alora G M; Grigsby J; Poulter B; Van Derveer JW; Giron SG; Jerome L; Feduccia AA; Hamilton S; Yazar-Klosinski B; Emerson A; Mithoefer MC; Doblin R
    J Psychopharmacol; 2018 Dec; 32(12):1295-1307. PubMed ID: 30371148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.
    Danforth AL; Grob CS; Struble C; Feduccia AA; Walker N; Jerome L; Yazar-Klosinski B; Emerson A
    Psychopharmacology (Berl); 2018 Nov; 235(11):3137-3148. PubMed ID: 30196397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample.
    Acheson D; Feifel D; de Wilde S; McKinney R; Lohr J; Risbrough V
    Psychopharmacology (Berl); 2013 Sep; 229(1):199-208. PubMed ID: 23644911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortisol administration after extinction in a fear-conditioning paradigm with traumatic film clips prevents return of fear.
    Brueckner AH; Lass-Hennemann J; Wilhelm FH; Ferreira de Sá DS; Michael T
    Transl Psychiatry; 2019 Apr; 9(1):128. PubMed ID: 30962423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition, extinction, and return of fear in veterans in intensive outpatient prolonged exposure therapy: A fear-potentiated startle study.
    Maples-Keller J; Watkins LE; Nylocks KM; Yasinski C; Coghlan C; Black K; Jovanovic T; Rauch SAM; Rothbaum BO; Norrholm SD
    Behav Res Ther; 2022 Jul; 154():104124. PubMed ID: 35642990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate pre-learning stress enhances baseline startle response and fear acquisition in a fear-potentiated startle paradigm.
    Riggenbach MR; Weiser JN; Mosley BE; Hipskind JJ; Wireman LE; Hess KL; Duffy TJ; Handel JK; Kaschalk MG; Reneau KE; Rorabaugh BR; Norrholm SD; Jovanovic T; Zoladz PR
    Behav Brain Res; 2019 Oct; 371():111980. PubMed ID: 31145979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice.
    Curry DW; Young MB; Tran AN; Daoud GE; Howell LL
    Neuropharmacology; 2018 Jan; 128():196-206. PubMed ID: 28993129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.